Novavax's John Trizzino spoke to BioPharmaDispatch as the company prepares to launch one of the world's first Phase 2 clinical trials of a combination COVID-19-influenza vaccine.
'It just seems logical and reasonable to bring the two vaccines together'
December 16, 2022 Latest NewsBioPharmaBioPharmaDispatch ExecutiveNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep.25
July 24, 2026 - - Podcast -
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News

